Eli Lilly and Company
[1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes

Abstract:

The present invention provides a compound of Formula I: wherein X is CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, OCH.sub.2, or CH.sub.2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH.sub.2CH.sub.2, then R is other than cyclopropyl; for use as a human PDE inhibitor. ##STR00001##